Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-Digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia.

Next Previous
Trial Profile

A Parallel, Double-blind, Placebo Controlled, Randomized Comparison of an Anti-Digoxin Antibody (Digibind) Versus Placebo for the Treatment of Antepartum Patients With Severe Preeclampsia.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-digoxin polyclonal antibody (Primary)
  • Indications Preeclampsia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms DEEP

    • Most Recent Events

    • 06 Jan 2011 Results have been published (American Journal of Perinatology; 27(8): 655-662).
    • 25 Sep 2008 Additional analysis presented at the 16th World Congress of the International Society for the Study of Hypertension in Pregnancy in Sep 2008.
    • 22 Jul 2008 Data are under review by a potential licensing partner; In addition, data from the study will be presented in international conferences later this year, reported by Protherics in a media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top